Zacks Research Upgrades Optimi Health (NASDAQ:OPTH) to Hold

Optimi Health (NASDAQ:OPTH) was upgraded by investment analysts at Zacks Research to a “hold” rating in a note issued to investors on Thursday,Zacks.com reports.

Separately, Weiss Ratings initiated coverage on Optimi Health in a research note on Thursday, May 21st. They issued a “sell (d-)” rating on the stock. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Optimi Health presently has an average rating of “Reduce”.

Optimi Health Stock Up 5.7%

Optimi Health stock opened at $5.97 on Thursday. Optimi Health has a 1-year low of $4.95 and a 1-year high of $6.40.

More Optimi Health News

Here are the key news stories impacting Optimi Health this week:

• Positive Sentiment: Australia’s updated Authorized Prescriber framework broadens access to psychedelic-assisted therapy, potentially increasing demand for Optimi’s psilocybin and MDMA products in a key regulated market. Article Title
• Neutral Sentiment: Diamond Equity initiated/updated earnings estimates for multiple periods, showing expectations for continued net losses rather than an immediate path to profitability. Article Title